Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorouracil + mitomycin
- Development stage
- Phase 3
- Lead developer
- Centre Francois Baclesse
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Fluorouracil + mitomycin is a combination chemotherapy regimen consisting of the antimetabolite fluorouracil (5-FU) and the antitumor antibiotic mitomycin-C. This combination is a standard-of-care component in the definitive treatment of locally advanced anal canal cancer, typically administered concurrently with radiation therapy (chemoradiotherapy). Fluorouracil, a pyrimidine analog, exerts its cytotoxic effect primarily by inhibiting thymidylate synthase, which disrupts DNA synthesis. Mitomycin-C acts as a bioreductive alkylating agent that induces DNA cross-linking, leading to cell cycle arrest and apoptosis. In the clinical trial context associated with Centre Francois Baclesse, this combination is evaluated alongside Simultaneously Integrated Boost Intensity-Modulated Radiation Therapy (SIB-IMRT) to optimize locoregional control and preserve anal sphincter function while reducing the non-hematological toxicities associated with conventional radiotherapy.
- Other names
- 5-FU + Mitomycin-C5-Fluorouracil + Mitomycin-C5-FU + MMCfluorouracil + mitomycin-C
02
Targets
DNATXNRD2 (Thioredoxin reductase 2)TS (Thymidylate synthase)
Beyond the preview
Go deeper on fluorouracil + mitomycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorouracil + mitomycin.